Advertisement


Jame Abraham, MD, on The JAVELIN and KEYNOTE-028 Study Results

2015 San Antonio Breast Cancer Symposium

Advertisement

Jame Abraham, MD, of the Cleveland Clinic, discusses findings on the use of avelumab, an anti–PD-L1 antibody, in patients with locally advanced or metastatic breast cancer, as well as the preliminary efficacy and safety findings of pembrolizumab in patients with PD-L1–positive, estrogen receptor–positive/HER2-negative disease (Abstracts S1-04, S5-07).



Related Videos

Breast Cancer

Hans Wildiers, MD, PhD on the TH3RESA Study: Final OS Results

Hans Wildiers, MD, PhD, of the University Hospitals, Leuven, discusses this phase III study on the use of ado-trastuzumab emtansine vs treatment of physician’s choice in previously treated HER2-positive metastatic breast cancer (Abstract S5-05).

Breast Cancer

Clifford Hudis, MD, and Julia White, MD, on Early-Stage Breast Cancer: Hypofractionated Radiotherapy

Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and Julia R. White, MD, of Ohio State University Comprehensive Cancer Center, discuss a meta-analysis on efficacy and safety of hypofractionated radiotherapy for the treatment of early-stage breast cancer (Abstract P3-12-15).

Breast Cancer

Sarat Chandarlapaty, MD, PhD, on BOLERO-2 Clinical Trial Results

Sarat Chandarlapaty, MD, PhD, of the Memorial Sloan Kettering Cancer Center, discusses results from this study that showed patients with ER-positive metastatic breast cancer who had a D538G and/or a Y537S mutation in the ESR1 gene had significantly worse median overall survival (Abstract S2-07).

Breast Cancer

Andrew Seidman, MD, and Norman Wolmark, MD, on NSABP Clinical Trials and Management of Early Breast Cancer

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Norman Wolmark, MD, of Allegheny General Hospital, discuss the landmark trials of NSABP that have led to profound changes in breast cancer treatment. (Abstract ML-1)

Breast Cancer

Jame Abraham, MD, on HER2-Positive Breast Cancer: Results of the BCIRG-006 Study

Jame Abraham, MD, of the Cleveland Clinic, discusses the 10-year follow-up of this trial, and the long-term benefit and safety of adding trastuzumab to the adjuvant treatment of HER2-positive early breast cancer (Abstract S5-04).

Advertisement

Advertisement




Advertisement